戻る Agenda
Real World Data to Real World Evidence
Session Chair(s)
Richard Zink
Principal Research Fellow
JMP Statistical Discovery, United States
We discuss the advantages and disadvantages of real world data and real world evidence compared to other sources. Join the Clinical Research Community for a follow up Round Table discussion on Wednesday, June 26, 9:30-10:30AM in the DIA Community Zone 1, Sails Pavilion.
Learning Objective : Describe the importance of real world data for answering regulatory questions; Discuss the benefits and challenges of evidence derived from real world sources compared to clinical trials.
Speaker(s)
Real World Data to Real World Evidence: A Case Study of Direct-Acting Antivirals for the Treatment of Hepatitis C Infection
Richard Zink
JMP Statistical Discovery, United States
Principal Research Fellow
Machine Learning 2.0: Causal Models and Big Data in the Era of Real World Evidence
Andrew Wilson, PHD, MS
Parexel, United States
Head of Innovative RWD Analytics
Matching with Replacement: The COLLECTION of ‘Personal’ EFFECTs Should be Handled with Care
Sarah Anselm Short, MPH
ICON plc., United States
Sr. Statistical Mgr, RWE - Biostats & Medical Writing